SkinBioTherapeutics plc “Essential external validation passed” Dr Catherine O’Neill, CEO

SkinBioTherapeutics plc LON:SBTX, a life science company focused on skin health, has passed third party cellular toxicity tests for its SkinBiotix(R) technology, confirming previous in-house observations on its safety and applicability.

Dr Catherine O’Neill, CEO of SkinBioTherapeutics, commented: “This announcement demonstrates the excellent progress SkinBioTherapeutics is making at all levels – scientific, development, manufacture and commercial.

“The result from the cytotoxicity testing by Charles River is essential external validation of our SkinBiotix(R) platform. This was one of the key milestones to pass and was highlighted as such at the IPO. Its passing marks a critical step in our progression and the transitioning of the technology into human validation studies.

“Operationally, we are on track. The development programmes are progressing well, we are generating further scientific data on SkinBiotix(R) confirming its suitability for application to skin, and industry awareness of our technology is growing.”

 

 

The Company has also been progressing its three programmes and is on track to hit its key milestone of first studies in man in 2018.

Cytotoxicity studies

The studies were conducted by Charles River, a Contract Research Organisation, in accordance with the OECD Principles of Good Laboratory Practice.

The objective of the toxicity tests was to determine if there were any adverse biological reactions from mammalian cell cultures following the use of SkinBioTherapeutics’ SkinBiotix(R) technology.

Following incubation for 24 hours, no cytotoxicity was observed e.g., malformation of cells or cell degeneration. The data confirm SkinBioTherapeutics’ in-house observations on how mammalian skin cells and fibroblasts respond to being exposed to SkinBiotix(R). This further supports the principle of SkinBiotix(R)’s suitability for use in skin care applications.

Two further tests, phototoxicity and in vitro ocular toxicity are scheduled. These results will be reported when the data is received.

Scientific update

As outlined at IPO in April 2017, SkinBioTherapeutics has been concentrating on further developing its technology towards the three applications in skin care, anti-infection and skin repair.

The positive cytotoxicity result above is a key milestone. However, other work is progressing well and the Company has summarised this below:

– Manufacture: work on scale-up has been initiated, confirmed by the successful manufacture of SkinBiotix(R) by an external partner

– Pilot scale formulation has been initiated by an external partner with expertise in cosmetic formulation development. Phase one of three is complete; testing of solubility and preservative requirements of the technology. Phase two, identifying a final blend for testing, is currently underway

– Early stage commercial discussions are ongoing with both potential manufacturing partners as well as potential licensees

   -      Anti-infection and eczema programmes

o A ‘time-course’ study, has confirmed that the frequency of application required for protection is three times daily. Therefore, protection against Staphylococcus aureus infection for both eczema and infection programmes requires application every five hours*

   -      Regulatory process has commenced and a regulatory consultant has been appointed 
   -      Ongoing scientific studies:

o Defining dosage is complete – for all three applications. SkinBioTherapeutics has finalised a dosing level at which the technology will be used which maintains the viability of the skin cells

o Confirmation of the modifying property of SkinBiotix(R) on protein composition of the skin, increasing the expression of Claudin 4, an essential component in tight junctions which are critical for the barrier characteristic of skin

*These data were recently presented at a Wellcome Trust conference: “Host Microbiome Interactions in Health and Disease”.

 

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    SkinBiotherapeutics Plc

    More articles like this

    SkinBiotherapeutics Plc

    Why we should all be eating a microbiome diet

    First, let’s briefly talk about the microbiome. The gut microbiome refers to the trillions of bacteria that live within our gastrointestinal tracts. If you were to collectively bunch them all up into a ball, it would

    SkinBiotherapeutics Plc

    Microbiome-based therapy for eczema: On the horizon?

    Results of pre-clinical and early clinical trials conducted by investigators at the National Institutes of Health showing the effectiveness of using bacteria to treat eczema are paving the way for further study into the potential for

    SkinBiotherapeutics Plc

    SkinBioTherapeutics plc achieved significant manufacturing scale up

    Dr Cath O’Neill, CEO of SkinBioTherapeutics, commented: “The progress we’ve made so far in manufacturing and freeze-drying the lysate is very encouraging. The current formulation is undergoing extended stability studies in preparation for the human study.”

    SkinBiotherapeutics Plc

    Protect your skin microbiome

    Like your gut, your skin also has a complex system of bacteria and fungi living on its surface. “It sounds weird and scary, but it’s actually good for you,” says Sarvenaz Zand, M.D., a dermatologist based

    SkinBiotherapeutics Plc

    What Is Dyshidrotic Eczema, Exactly?

    If you have found your way to this story, then there is a good chance you’re feeling the itch. Dyshidrotic Eczema is a common form of eczema that can crop up as crazy itchy blisters on

    SkinBiotherapeutics Plc

    Bacteria on your skin could speed healing

    Microbes on the surface of the skin help the immune system to respond to injury and heal wounds. Immunity research have historically focused on the response to pathogens and inflammation, and so relatively little is known

    SkinBiotherapeutics Plc

    Can you really use probiotics to fight acne?

    If you’ve ever had a breakout, you’ve likely tried to dry those suckers up with bacteria-killing washes and spot treatments. You know, because conventional wisdom (and lots of research) has shown that zits, particularly the big painful

    SkinBiotherapeutics Plc

    SkinBiotherapeutics is harnessing the power of Microbiome

    SkinBioTherapeutics (LON:SBTX) CEO Dr Cath O’Neill worked in the field of gastroenterology, investigating the effect of probiotics on the intestinal barrier function, an area which had already seen significant commercial success through health foods and yoghurt

    SkinBiotherapeutics Plc

    Skin Microbiome: Why You want Bacteria On Your Skin

    The gut gets the majority of the attention when we talk about the microbiome (even though your mouth has a vast microbiome as well!). The digestive system is home to trillions of organisms that can affect the body,